Medication Regimen Design in CKD: A Primer on Pharmacokinetics (in CKD Non-Dialysis)
A majority of medications are primarily eliminated by the kidneys. As kidney function declines in chronic kidney disease, altered pharmacokinetics necessitate dosage adjustment to minimize toxicity risk while ensuring optimal efficacy. This module will provide the underpinning pharmacokinetic rationale for these medication dosage adjustments, using practical examples of commonly used medications in clinical practice.
By the end of this module, learners will be able to:
- Describe clinically relevant changes in pharmacokinetics (PK) and pharmacodynamics (PD) that occur as kidney function declines.
- Differentiate data derived from PK studies and outcomes studies to make drug therapy decisions.
- Design a medication regimen and monitoring plan for high-risk medications in patients with chronic kidney disease (CKD).
- Design strategies to engage patients and caregivers in the design of their medication regimen to promote efficacy and safety.
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Wendy St. Peter, PharmD, FCCP, FASN, FNKF - Consultant [GSK, Boehringer-Ingelheim/Lilly, Bayer]
- Marissa Battistella, PharmD - Speakers Bureau: Otsuka Canada- honorarium for presentations
- Patrick Gee, PhD - Speaker's Bureau: Boehringer Ingelheim, UCAR & eGFR blood test, March 2024
- Max Smith, PharmD - Grants/Research Support: Kailos Genetics, Inc. - funds to institution - support ended July 2023
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for .75 hours AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded .75 contact hours of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for .75 contact hours. UAN: JA4008105-9999-24-038-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.
